Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on June 10, 2025. The filing was submitted on June 11, 2025. The Company acted through its corporate stockbroker, Merrill Lynch International, to purchase ordinary shares as part of an existing buyback programme.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than comprehensive financial statements. Key metrics for the transaction on June 10, 2025, include:
- Shares Purchased: 374,145 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,492.00p; highest price paid was 1,511.50p.
- Average Price: Volume-weighted average price paid was 1,502.58p.
- Trading Venue: All purchases were executed on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, the Company holds 219,945,254 ordinary shares in treasury.
- Shares in Issue: 4,095,337,657 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.37% of total voting rights.
Material Changes and Programme Progress
This purchase was effected pursuant to a non-discretionary agreement entered into with the broker on June 4, 2025. Since the commencement of this specific agreement on June 4, 2025, the Company has purchased a total of 1,810,871 ordinary shares. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a transaction report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific document.
Investor Verification Checklist
- Verify the total number of treasury shares held (219,945,254) against the latest Form 20-F or quarterly reports to confirm the 5.37% voting rights calculation.
- Confirm the remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Review the referenced "Risk Factors" in the 2024 Form 20-F and Q1 2025 results for context on the forward-looking statements mentioned.
- Monitor subsequent filings for updates on the non-discretionary agreement initiated on June 4, 2025.